Pentraxin 3 in unstable angina and non-ST-segment elevation myocardial infarction

Shigeru Matsui, Junichi Ishii, Fumihiko Kitagawa, Atsuhiro Kuno, Kousuke Hattori, Makoto Ishikawa, Masanori Okumura, Shino Kan, Tadashi Nakano, Hiroyuki Naruse, Ikuko Tanaka, Masanori Nomura, Hitoshi Hishida, Yukio Ozaki

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Purpose: We prospectively investigated the prognostic value of pentraxin 3 (PTX3) in patients with unstable angina and non-ST-segment elevation myocardial infarction (UA/NSTEMI). Background: PTX3 may be a useful marker for localized vascular inflammation and damage to the cardiovascular system. Recent studies have shown that plasma PTX3 is elevated in patients with UA/NSTEMI; however, its prognostic value in UA/NSTEMI remains unclear. Methods: PTX3, high-sensitivity C-reactive protein (hsCRP), N-terminal pro-B-type natriuretic peptide (NT-proBNP), and cardiac troponin I were measured on admission in 204 consecutive patients (mean age of 69 years; 144 males) hospitalized for UA/NSTEMI within 24. h (mean of 7.5. h) after the onset of chest symptoms. A cardiac event, which was defined as cardiac death, rehospitalization for acute coronary syndrome (ACS), or rehospitalization for worsening heart failure, was monitored for 6 months after admission. Results: A total of 26 (13%) cardiac events occurred during the 6-month follow-up period. In a stepwise Cox regression analysis including 18 well-known clinical and biochemical predictors of ACS outcome, both PTX3 (relative risk 3.86 per 10-fold increment, P= 0.01) and NT-proBNP (relative risk 2.16 per 10-fold increment, P=0.02), but not hsCRP, were independently associated with the 6-month cardiac event. The cardiac event rate was higher in patients with increased PTX3 (≥3.1. ng/mL of median value) than those without (20% vs. 5.8%, P=0.003). A Kaplan-Meier analysis revealed that patients with increased PTX3 had a higher risk for cardiac events than those without (P=0.002). Conclusion: PTX3 and NT-proBNP may be potent and independent predictors for 6-month cardiac events in patients hospitalized for UA/NSTEMI within 24. h after the onset. Measurement of plasma PTX3 may substantially improve the early risk stratification of patients with UA/NSTEMI.

Original languageEnglish
Pages (from-to)220-225
Number of pages6
JournalAtherosclerosis
Volume210
Issue number1
DOIs
Publication statusPublished - 01-05-2010

Fingerprint

Unstable Angina
Brain Natriuretic Peptide
Acute Coronary Syndrome
C-Reactive Protein
Non-ST Elevated Myocardial Infarction
PTX3 protein
Troponin I
Kaplan-Meier Estimate
Cardiovascular System
Blood Vessels
Thorax
Heart Failure
Regression Analysis
Inflammation

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Matsui, Shigeru ; Ishii, Junichi ; Kitagawa, Fumihiko ; Kuno, Atsuhiro ; Hattori, Kousuke ; Ishikawa, Makoto ; Okumura, Masanori ; Kan, Shino ; Nakano, Tadashi ; Naruse, Hiroyuki ; Tanaka, Ikuko ; Nomura, Masanori ; Hishida, Hitoshi ; Ozaki, Yukio. / Pentraxin 3 in unstable angina and non-ST-segment elevation myocardial infarction. In: Atherosclerosis. 2010 ; Vol. 210, No. 1. pp. 220-225.
@article{1601b4bb31704b88a74c28ade83b2b6b,
title = "Pentraxin 3 in unstable angina and non-ST-segment elevation myocardial infarction",
abstract = "Purpose: We prospectively investigated the prognostic value of pentraxin 3 (PTX3) in patients with unstable angina and non-ST-segment elevation myocardial infarction (UA/NSTEMI). Background: PTX3 may be a useful marker for localized vascular inflammation and damage to the cardiovascular system. Recent studies have shown that plasma PTX3 is elevated in patients with UA/NSTEMI; however, its prognostic value in UA/NSTEMI remains unclear. Methods: PTX3, high-sensitivity C-reactive protein (hsCRP), N-terminal pro-B-type natriuretic peptide (NT-proBNP), and cardiac troponin I were measured on admission in 204 consecutive patients (mean age of 69 years; 144 males) hospitalized for UA/NSTEMI within 24. h (mean of 7.5. h) after the onset of chest symptoms. A cardiac event, which was defined as cardiac death, rehospitalization for acute coronary syndrome (ACS), or rehospitalization for worsening heart failure, was monitored for 6 months after admission. Results: A total of 26 (13{\%}) cardiac events occurred during the 6-month follow-up period. In a stepwise Cox regression analysis including 18 well-known clinical and biochemical predictors of ACS outcome, both PTX3 (relative risk 3.86 per 10-fold increment, P= 0.01) and NT-proBNP (relative risk 2.16 per 10-fold increment, P=0.02), but not hsCRP, were independently associated with the 6-month cardiac event. The cardiac event rate was higher in patients with increased PTX3 (≥3.1. ng/mL of median value) than those without (20{\%} vs. 5.8{\%}, P=0.003). A Kaplan-Meier analysis revealed that patients with increased PTX3 had a higher risk for cardiac events than those without (P=0.002). Conclusion: PTX3 and NT-proBNP may be potent and independent predictors for 6-month cardiac events in patients hospitalized for UA/NSTEMI within 24. h after the onset. Measurement of plasma PTX3 may substantially improve the early risk stratification of patients with UA/NSTEMI.",
author = "Shigeru Matsui and Junichi Ishii and Fumihiko Kitagawa and Atsuhiro Kuno and Kousuke Hattori and Makoto Ishikawa and Masanori Okumura and Shino Kan and Tadashi Nakano and Hiroyuki Naruse and Ikuko Tanaka and Masanori Nomura and Hitoshi Hishida and Yukio Ozaki",
year = "2010",
month = "5",
day = "1",
doi = "10.1016/j.atherosclerosis.2009.10.033",
language = "English",
volume = "210",
pages = "220--225",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

Matsui, S, Ishii, J, Kitagawa, F, Kuno, A, Hattori, K, Ishikawa, M, Okumura, M, Kan, S, Nakano, T, Naruse, H, Tanaka, I, Nomura, M, Hishida, H & Ozaki, Y 2010, 'Pentraxin 3 in unstable angina and non-ST-segment elevation myocardial infarction', Atherosclerosis, vol. 210, no. 1, pp. 220-225. https://doi.org/10.1016/j.atherosclerosis.2009.10.033

Pentraxin 3 in unstable angina and non-ST-segment elevation myocardial infarction. / Matsui, Shigeru; Ishii, Junichi; Kitagawa, Fumihiko; Kuno, Atsuhiro; Hattori, Kousuke; Ishikawa, Makoto; Okumura, Masanori; Kan, Shino; Nakano, Tadashi; Naruse, Hiroyuki; Tanaka, Ikuko; Nomura, Masanori; Hishida, Hitoshi; Ozaki, Yukio.

In: Atherosclerosis, Vol. 210, No. 1, 01.05.2010, p. 220-225.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pentraxin 3 in unstable angina and non-ST-segment elevation myocardial infarction

AU - Matsui, Shigeru

AU - Ishii, Junichi

AU - Kitagawa, Fumihiko

AU - Kuno, Atsuhiro

AU - Hattori, Kousuke

AU - Ishikawa, Makoto

AU - Okumura, Masanori

AU - Kan, Shino

AU - Nakano, Tadashi

AU - Naruse, Hiroyuki

AU - Tanaka, Ikuko

AU - Nomura, Masanori

AU - Hishida, Hitoshi

AU - Ozaki, Yukio

PY - 2010/5/1

Y1 - 2010/5/1

N2 - Purpose: We prospectively investigated the prognostic value of pentraxin 3 (PTX3) in patients with unstable angina and non-ST-segment elevation myocardial infarction (UA/NSTEMI). Background: PTX3 may be a useful marker for localized vascular inflammation and damage to the cardiovascular system. Recent studies have shown that plasma PTX3 is elevated in patients with UA/NSTEMI; however, its prognostic value in UA/NSTEMI remains unclear. Methods: PTX3, high-sensitivity C-reactive protein (hsCRP), N-terminal pro-B-type natriuretic peptide (NT-proBNP), and cardiac troponin I were measured on admission in 204 consecutive patients (mean age of 69 years; 144 males) hospitalized for UA/NSTEMI within 24. h (mean of 7.5. h) after the onset of chest symptoms. A cardiac event, which was defined as cardiac death, rehospitalization for acute coronary syndrome (ACS), or rehospitalization for worsening heart failure, was monitored for 6 months after admission. Results: A total of 26 (13%) cardiac events occurred during the 6-month follow-up period. In a stepwise Cox regression analysis including 18 well-known clinical and biochemical predictors of ACS outcome, both PTX3 (relative risk 3.86 per 10-fold increment, P= 0.01) and NT-proBNP (relative risk 2.16 per 10-fold increment, P=0.02), but not hsCRP, were independently associated with the 6-month cardiac event. The cardiac event rate was higher in patients with increased PTX3 (≥3.1. ng/mL of median value) than those without (20% vs. 5.8%, P=0.003). A Kaplan-Meier analysis revealed that patients with increased PTX3 had a higher risk for cardiac events than those without (P=0.002). Conclusion: PTX3 and NT-proBNP may be potent and independent predictors for 6-month cardiac events in patients hospitalized for UA/NSTEMI within 24. h after the onset. Measurement of plasma PTX3 may substantially improve the early risk stratification of patients with UA/NSTEMI.

AB - Purpose: We prospectively investigated the prognostic value of pentraxin 3 (PTX3) in patients with unstable angina and non-ST-segment elevation myocardial infarction (UA/NSTEMI). Background: PTX3 may be a useful marker for localized vascular inflammation and damage to the cardiovascular system. Recent studies have shown that plasma PTX3 is elevated in patients with UA/NSTEMI; however, its prognostic value in UA/NSTEMI remains unclear. Methods: PTX3, high-sensitivity C-reactive protein (hsCRP), N-terminal pro-B-type natriuretic peptide (NT-proBNP), and cardiac troponin I were measured on admission in 204 consecutive patients (mean age of 69 years; 144 males) hospitalized for UA/NSTEMI within 24. h (mean of 7.5. h) after the onset of chest symptoms. A cardiac event, which was defined as cardiac death, rehospitalization for acute coronary syndrome (ACS), or rehospitalization for worsening heart failure, was monitored for 6 months after admission. Results: A total of 26 (13%) cardiac events occurred during the 6-month follow-up period. In a stepwise Cox regression analysis including 18 well-known clinical and biochemical predictors of ACS outcome, both PTX3 (relative risk 3.86 per 10-fold increment, P= 0.01) and NT-proBNP (relative risk 2.16 per 10-fold increment, P=0.02), but not hsCRP, were independently associated with the 6-month cardiac event. The cardiac event rate was higher in patients with increased PTX3 (≥3.1. ng/mL of median value) than those without (20% vs. 5.8%, P=0.003). A Kaplan-Meier analysis revealed that patients with increased PTX3 had a higher risk for cardiac events than those without (P=0.002). Conclusion: PTX3 and NT-proBNP may be potent and independent predictors for 6-month cardiac events in patients hospitalized for UA/NSTEMI within 24. h after the onset. Measurement of plasma PTX3 may substantially improve the early risk stratification of patients with UA/NSTEMI.

UR - http://www.scopus.com/inward/record.url?scp=77952427038&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952427038&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosis.2009.10.033

DO - 10.1016/j.atherosclerosis.2009.10.033

M3 - Article

C2 - 19945702

AN - SCOPUS:77952427038

VL - 210

SP - 220

EP - 225

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 1

ER -